Stock Crash: Pharma stock extends losses after Q2 results; down 27% in 11 sessions
Published on: Nov. 13, 2025, 11:34 a.m. | Source: CNBC TV18
The near-term growth has been weighed down by pharma destocking, project delays of 2-3 quarters at NJ Bio due to slower biotech funding, and extended CMC timelines from partners.
